Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project.
Franchi M, Vener C, Garau D, Kirchmayer U, Di Martino M, Romero M, De Carlo I, Scondotto S, Stival C, Della Porta MG, Passamonti F, Corrao G. Franchi M, et al. Among authors: passamonti f. Ther Adv Hematol. 2021 Feb 23;12:2040620721996488. doi: 10.1177/2040620721996488. eCollection 2021. Ther Adv Hematol. 2021. PMID: 33747423 Free PMC article.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Among authors: passamonti f. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Passamonti F, et al. Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13. Lancet Haematol. 2020. PMID: 32798473 Free PMC article.
Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis.
Mora B, Siracusa C, Rumi E, Maffioli M, Casetti IC, Barraco D, Merli M, Rossi M, Ubezio M, Accetta R, Libera L, Pietra D, Trotti C, Uccella S, Pallotti F, Casalone R, Bertù L, Arcaini L, Della Porta MG, Passamonti F. Mora B, et al. Among authors: passamonti f. Leukemia. 2021 May;35(5):1490-1493. doi: 10.1038/s41375-020-01053-9. Epub 2020 Oct 13. Leukemia. 2021. PMID: 33051550 No abstract available.
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. Bersanelli M, et al. Among authors: passamonti f. J Clin Oncol. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539200 Free PMC article.
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years.
Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, Bersanelli M, Mandelli S, Antonella Galbussera A, Mosca E, Saba E, Chiereghin C, Manes N, Milanesi C, Ubezio M, Morabito L, Peano C, Soldà G, Asselta R, Duga S, Selmi C, De Santis M, Malik K, Maggioni G, Bicchieri M, Campagna A, Tentori CA, Russo A, Civilini E, Allavena P, Piazza R, Corrao G, Sala C, Termanini A, Giordano L, Detoma P, Malabaila A, Sala L, Rosso S, Zanetti R, Saitta C, Riva E, Condorelli G, Passamonti F, Santoro A, Sole F, Platzbecker U, Fenaux P, Bolli N, Castellani G, Kern W, Vassiliou GS, Haferlach T, Lucca U, Della Porta MG. Rossi M, et al. Among authors: passamonti f. Blood. 2021 Nov 25;138(21):2093-2105. doi: 10.1182/blood.2021011320. Blood. 2021. PMID: 34125889 Free PMC article. Clinical Trial.
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, Cattaneo C, Bonuomo V, Busca A, Ferreri AJM, Bruna R, Petrucci L, Cairoli R, Salvini M, Bertù L, Ladetto M, Pilerci S, Pinto A, Ramadan S, Marchesi F, Cavo M, Arcaini L, Coviello E, Romano A, Musto P, Massaia M, Fracchiolla N, Marchetti M, Scattolin A, Tisi MC, Cuneo A, Della Porta M, Trentin L, Turrini M, Gherlinzoni F, Tafuri A, Galimberti S, Bocchia M, Cardinali V, Cilloni D, Corso A, Armiento D, Rigacci L, La Barbera EO, Gambacorti-Passerini C, Visani G, Vallisa D, Venditti A, Selleri C, Conconi A, Tosi P, Lanza F, Candoni A, Krampera M, Corradini P, Passamonti F, Merli F; ITA-HEMA-COV investigators. Visco C, et al. Among authors: passamonti f. Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691. Blood Adv. 2022. PMID: 34644385 Free PMC article.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall A, Passamonti F. Maffioli M, et al. Among authors: passamonti f. Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889. Blood Adv. 2022. PMID: 35130339 Free PMC article.
409 results